142 related articles for article (PubMed ID: 37401656)
1. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
2. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy.
Zhang J; Yang F; Mei X; Yang R; Lu B; Wang Z; Ji L
Chem Biol Interact; 2022 Jan; 351():109739. PubMed ID: 34742683
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
4. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
5. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
6. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
[TBL] [Abstract][Full Text] [Related]
7. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of Asparagus racemosus willd. and Withania somnifera (L.) Dunal as chemotherapeutic adjuvants for breast cancer treatment.
Prasad K; Saggam A; Guruprasad KP; Tillu G; Patwardhan B; Satyamoorthy K
J Ethnopharmacol; 2024 Sep; 331():118261. PubMed ID: 38685363
[TBL] [Abstract][Full Text] [Related]
10. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
12. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
[TBL] [Abstract][Full Text] [Related]
13. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and anti-triple negative breast cancer activity of novel Toosendanin derivatives.
Zhang H; Chen Y; Liu Q; Xiao WW; Shao LD; Pan ZH; Chen CH; Li D
Bioorg Med Chem Lett; 2023 Mar; 83():129187. PubMed ID: 36781147
[TBL] [Abstract][Full Text] [Related]
15. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
16. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
17. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
18. Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Cordani N; Lisini D; Coccè V; Paglia G; Meanti R; Cerrito MG; Tettamanti P; Bonaffini L; Paino F; Alessandri G; Marcianti A; Giannì A; Villa C; Mauri M; Mologni L; Torsello A; Pessina A; Cazzaniga ME
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982938
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
